Baron Discovery Fund Gains in Q2 2026 With CareDx Highlight
Baron Capital’s Q2 2026 investor letter described a 19.08% gain for the Baron Discovery Fund (Institutional Shares) in the quarter, though it trailed the Russell 2000 Growth Index. CareDx’s transplant diagnostics helped the fund’s results. CareDx shares fell in Q3 2025 after CMS issued a draft MolDX LCD that could significantly limit reimbursement and outline a bundled payment model recommended by medical societies.